PNP10: COST-EFFECTIVENESS OF ATOMOXETINE IN THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER IN CHILDREN AND ADOLESCENTS  by Iskedjian, M et al.
275Abstracts
PNP10
COST-EFFECTIVENESS OF ATOMOXETINE IN
THE TREATMENT OF ATTENTION DEFICIT
HYPERACTIVITY DISORDER IN CHILDREN 
AND ADOLESCENTS
Iskedjian M1, Maturi B1,Walker JH2, Einarson TR3, Khattak S4,
Carter G4
1PharmIdeas Research and Consulting Inc, Oakville, ON,
Canada; 2Brock University, St. Catharines, ON, Canada;
3University of Toronto,Toronto, ON, Canada; 4The Kids Clinic,
Whitby, ON, Canada
OBJECTIVE: Attention deﬁcit hyperactivity disorder
(ADHD) affects 3%–5% of North Americans <18 years
of age. We conducted a cost-effectiveness (CE) analysis 
of atomoxetine (ATO), a new non-stimulant, against
methylphenidate (MTP) in ADHD. METHODS: Using
TreeAge Data 4.0, we constructed a six-month decision
analytic model. We included preference rates for non-
stimulant over stimulant medication, determined by sur-
veying parents of ADHD children. Efﬁcacy and resource
use data were determined from the literature and expert
opinion. Perspectives considered were: Ontario Ministry
of Health (MoH), which included direct medical costs
(physician visits and drug costs); government (MoH and
Ontario Ministry of Education), which included MoH
costs plus costs of school-based drug administration 
and special education; and society, including the former
costs plus non-pharmacologic interventions such as psy-
chotherapy and over the counter supplements. Prices were
obtained from standard lists and measured in 2002 Cana-
dian dollars. Effectiveness was measured as the number
of symptom free days (SFDs), deﬁned as days of success-
ful treatment. SFDs were assigned for the 2-week period
prior to assessments of successful treatment and for each
successful day remaining in the subsequent cycles. Pref-
erence rates for ATO were varied in a sensitivity analysis
from 57–93% based on 95% conﬁdence intervals of the
normalized ATO rate. RESULTS: In the MoH base-case
analysis for ATO and MTP, respectively, expected costs
were $678 and $162, SFDs were 156 and 98. The incre-
mental cost effectiveness ratio (ICER) was $8.87/addi-
tional SFD for MoH perspective, $8.83/additional SFD
from the government perspective, and $2.00/additional
SFD for societal. In the sensitivity analysis of preference
rates, ICERs ranged from $1.12/SFD (societal) to
$20.34/SFD (MoH perspective). CONCLUSION: We
found a strong preference for non-stimulant therapy,
whose incremental cost was relatively small and quite 
reasonable.
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OBJECTIVES: To examine the medical care costs paid by
commercial health plans for treating attention deﬁcit/
hyperactivity disorder (ADHD) in their health plans.
METHODS: We used a nationally representative claim
data set (Pharmetrics claim database) with 23 million
covered lives and 28 health plans. ADHD patients at dif-
ferent age groups were identiﬁed base on ICD-9 codes.
The mean annual medical care costs for treating ADHD
were calculated for each age group from the medical care
claims that have ADHD ICD-9 codes as principal diag-
nosis. The medical care costs examined in this study
include the costs reimbursed by commercial health plans
for all outpatient services, mental health services, emer-
gency services, and inpatient services claims with ADHD
ICD-9 codes as principal diagnoses, but exclude all 
medication costs. RESULTS: More than 15,000 ADHD
patients were identiﬁed from Pharmetrics data set in year
2000. The mean annual medical care costs for different
age groups were calculated as follows: $221.92 for chil-
dren under age 6; $257 for children age between 6 and
11; $262.71 for teen ages between 12–18; and $202.94
for adults. Using these estimates and assuming 3% preva-
lence of ADHD nationwide, we can extrapolate that, each
year, at least more than $100 millions of medical care
have been consumed for treating ADHD. CONCLU-
SIONS: In addition to medication, ADHD patients in
commercial health plans also consume a signiﬁcant
amount of medical care for treating ADHD. This con-
sumption imposes a ﬁnancial burden to health plans.
Therefore, a new therapeutic approach that can reduce
this burden and has the same therapeutic efﬁcacy should
be encouraged.
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OBJECTIVES: To model the treatment patterns of
ADHD and to assess health economic differences between
standard immediate-release methylphenidate (MPH-IR)
(OD, BID or TID); a new orally administered, once-daily
(OD), long-acting (LA) formulation of methylphenidate
using a unique osmotic release delivery technology
(MPH-OD, LA); and behavioural therapy (BEH) in the
UK. The use of MPH-OD, LA minimizes ﬂuctuations in
peak-trough concentrations improving acute tolerance.
METHODS: Based on a clinical trial by the MTA Coop-
erative Group, a medical decision tree was developed in
MS-Excel, reﬂecting the current treatment strategies and
associated outcomes. The proﬁle for MPH-OD, LA was
determined based on a short-term comparative double-
blind cross-over trial and a 24-month open-label multi-
